Mitochondria are implicated in diseases affecting over a billion people globally, yet for decades, mitochondrial research has been constrained by a four-hour viability window. Mitovon Biosciences developed MitoCPS™ to extend that window to one year—making research faster, cheaper, and more accessible across pharma, industrial biotechnology, and agriculture.